Yocca Frank
Chief Scientific Officer
Yocca Frank has filed 6 SEC Form 4 filings (10 transaction rows) across 1 company, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Jun 17, 2026.
On the most recent filing, Yocca Frank is listed as Chief Scientific Officer at BioXcel Therapeutics, Inc. Inside the rolling window, Yocca Frank reported no open-market purchases and 1 open-market sale totaling $7K in BTAI.
Companies traded
Other insiders at BTAI
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$7K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Yocca Frank made?
Yocca Frank has filed 6 SEC Form 4 filings (10 transaction rows) across 1 company since 2025.
Which companies does Yocca Frank trade?
Yocca Frank has filed SEC Form 4 disclosures for 1 company, including BTAI.
When was Yocca Frank's most recent SEC Form 4 filing?
Yocca Frank's most recent SEC Form 4 filing on Tracefour is dated Jun 17, 2026.
What is Yocca Frank's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Yocca Frank is listed as Chief Scientific Officer.
What is Yocca Frank's total buy and sell value in the current window?
Inside the rolling retention window, Yocca Frank bought $0 and sold $7K based on SEC Form 4 filings.
What was Yocca Frank's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 6,845 BTAI shares on 2026-05-20, worth $7K, per SEC Form 4 filings.